natgillin/translations-raw huggingface dataset:
Increased saliva production, heartburn, numb around mouth
pojačano stvaranje sline, žgaravica, utrnulost oko usta
Increased saliva production, heartburn, numb around mouth.
pojačano stvaranje sline, žgaravica, utrnulost oko usta
increased sensation
pojačani osjeti
increased sensitivity of skin to sun
povećana osjetljivost kože na sunce
increased sensitivity of sound, taste or touch or changes in smell
povećana osjetljivost na zvuk, okus ili dodir ili promjene osjeta mirisa
increased sensitivity of the eyes or the skin to light
pojačana osjetljivost očiju ili kože na svjetlo
increased sensitivity of the skin to sunlight decreased feeling or sensitivity, especially in the skin
povećana osjetljivost kože na sunčevu svjetlost smanjen osjet, osobito kože
increased sensitivity to light floating spots before the eyes
povećanu osjetljivost na svjetlost lebdeće mrlje pred očima
increased sensitivity to light, appearance of flashing lights
pojačanu osjetljivost na svjetlost, bljeskanje pred očima
increased sensitivity to pain
pojačana osjetljivost na bol
increased sensitivity to pain
povećana osjetljivost na bol
Increased serum glutamic pyruvic transaminase activity also occurred in one of four dogs.
Povećana aktivnost serumske glutamat-piruvat transaminaze također se pojavila u jednog od četiri psa.
increased sex drive
pojačan spolni nagon
increased sex drive
pojačan spolni nagon,
Increased sexual desire
Pojačana spolna želja
Increased side effects may occur in case of recent or concomitant use of hepatotoxicor haematotoxic drugs or when leflunomide treatment is followed by such drugs without a washout period (see also guidance concerning combination with other treatments, section 4.4).
Više nuspojava može se pojaviti u slučaju nedavne ili istodobne primjene hepatotoksičnih ili hematotoksičnih lijekova ili kad se nakon primjene takvih lijekova leflunomid primjenjuje bez perioda ispiranja (vidjeti upute o kombinaciji s ostalim lijekovima, dio 4.4.).
increased skin sensitivity
pojačana osjetljivost kože na svjetlo
increased skin sensitivity (especially to hot and cold)
pojačana osjetljivost kože (osobito na toplinu i hladnoću)
increased skin sensitivity to sunlight
pojačana osjetljivost kože na sunčevu svjetlost
increased skin sensitivity to sunlight
povećana osjetljivost kože na sunčevu svjetlost
increased skin sensitivity, skin pain
povećana osjetljivost kože, kožna bol
increased sodium or magnesium, ketones in the blood and urine (ketoacidosis), renal function tests abnormal, kidney failure
povećana razina natrija ili magnezija, ketoni u krvi i mokraći (ketoacidoza), poremećeni testovi bubrežne funkcije, zatajenje bubrega
Increased spleen size and cases of spleen ruptures have been reported.
Zabilježeni su povećanje slezene i slučajevi prsnuća slezene.
Increased spleen size has been reported uncommonly (may affect up to 1 in 100 people) and cases of splenic ruptures have been reported with other medicines similar to Lonquex.
Povećana slezena zabilježena je vrlo rijetko (može utjecati na 1 od 100 osoba) i slučajevi prsnuća slezene zabilježeni su uz druge lijekove slične Lonquexu.
increased spleen size. spleen rupture.
povećanje slezene. prsnuće slezene.
increased spontaneous bleeding in patients with haemophilia, anemia including acute haemolytic anaemia, thrombocytopenia (see section 4.4).
pojačano spontano krvarenje u bolesnika s hemofilijom, anemija uključujući i akutnu hemolitičku anemiju, trombocitopenija (vidjeti dio 4.4)
increased sugar in blood
povišena razina šećera u krvi
increased sugar in the blood
povišena razina šećera u krvi
increased sugar in the blood, loss of weight
povišena razina šećera u krvi, gubitak težine
increased sugar level (shown in blood tests) increased liver pigment (called “bilirubin”) in the blood.
povišena vrijednost šećera (vidljiva u nalazima krvnih pretraga)
increased sugar, fatty acids (triglycerides), bilirubin in your blood
povišene razine šećera, masnih kiselina (triglicerida), bilirubin u krvi
increased susceptibility to infection
povećana sklonost infekcijama
Increased sweating
Pojačano znojenje
increased sweating hardness, redness, swelling or bruising at the injection site
pojačano znojenje otvrdnuće, crvenilo, oticanje ili stvaranje modrica na mjestu injiciranja
increased sweating weakness, shivering
pojačano znojenje slabost, drhtanje
increased sweating,
pojačano znojenje,
increased sweating, (itchy) rash
pojačano znojenje, osip (koji svrbi)
increased sweating, (itchy) rash;
pojačano znojenje, osip (koji svrbi)
Increased sweating, night sweats
Pojačano znojenje, znojenje po noći
increased sweating, rashes
pojačano znojenje, osip
Increased sweating.
Pojačano znojenje.
increased sweating;
povećano znojenje,
increased sweating; hair loss; itching; dry skin; oily skin
pojačano znojenje; gubitak kose; svrbež; suha koža; masna koža
increased tear production
pojačano stvaranje suza
increased tearing
pojačano suzenje
Increased temperature, chills (signs of infection)
Povišena temperatura, zimica (znakovi infekcije)
increased temperature, hot flushes
povišena temperatura, navale vrućine
Increased tendency to bruise
pojačana sklonost nastanku modrica
Increased tendency to bruise
povećana sklonost prema stvaranju modrica
Increased tendency to bruise Hot flush
povećana sklonost prema stvaranju modrica
increased tendency to bruise, dry skin, psoriasis, skin redness, excessive sweating
povećana sklonost stvaranju modrica, suha koža, psorijaza, crvenilo kože, prekomjerno znojenje
increased tiredness
povećan umor
increased to 400 mg twice daily
povisiti na 400 mg dvaput na dan,
Increased total bilirubin
kiseline10
increased total bilirubin, neutropaenia, hypermagnesaemia, hypernatraemia, weight decreased
povišene razine ukupnog bilirubina, neutropenija, hipermagnezijemija, hipernatrijemija, smanjena tjelesna težina
increased total bilirubin,b decreased absolute neutrophil count,b hypermagnesaemia,b, hypernatraemiab
povišene razine ukupnog bilirubinab, smanjen apsolutni broj neutrofilab, hipermagnezijemijab, hipernatrijemijab
Increased total blood cholesterol levels.
Povišene razine ukupnog kolesterola u krvi.
increased total cholesterol (fasted) increased LDL cholesterol (fasted)
povišen ukupni kolesterol (natašte) povišen LDL kolesterol (natašte)
increased total cholesterol (fasted)2, increased LDL-cholesterol (fasted)2, hypophosphataemia3, 5
povišen ukupni kolesterol (natašte)2, povišen LDL kolesterol (natašte)2, hipofosfatemija3, 5
increased transaminases
povišene vrijednosti transaminaza
increased transaminases (AST and/or ALT)1, 2, 3
povišene transaminaze (AST i/ili ALT)1, 2, 3
Increased transaminases were reported in 24.2% of patients in clinical studies.
U kliničkim ispitivanjima povišene vrijednosti transaminaza prijavljene su u 24,2% bolesnika.
Increased triglycerides
Povišene vrijednosti triglicerida
increased triglycerides (fatty acids), bile or sugar in the blood liver and pancreas problems
povišene trigliceride (masne kiseline), bilirubin (žučna boja) ili šećer u krvi poteškoće s jetrom i gušteračom
increased triglycerides (fatty acids), bile or sugar in the blood liver and pancreas problems
povišene trigliceride (masne kiseline), bilirubin (žučna boja) ili šećer u krvi tegobe s jetrom ili gušteračom
increased triglycerides (fatty acids), bile or sugar in the blood, liver and pancreas problems.
povišene razine triglicerida (masne kiseline), bilirubina ili šećera u krvi tegobe s jetrom ili gušteračom
Increased upper airway secretion
Povećana sekrecija gornjih dišnih puteva
increased uric acid in the blood
povećana razina mokraćne kiseline u krvi
increased uric acid in the blood;
povećana razina mokraćne kiseline u krvi,
Increased urinary glucose excretion was maintained at the end of the 4-week treatment period, averaging approximately
Povećano izlučivanje glukoze u mokraći održalo se pri kraju 4-tjednog perioda liječenja iznoseći u prosjeku približno
Increased use, including use of the product deviating from the instructions given above, may increase the prevalence of bacteria resistant to ceftiofur.
Povećana primjena uključujući upotrebu proizvoda koja odstupa od prethodnih uputa, može povećati prevalenciju bakterija otpornih na ceftiofur.
Increased use, including use of the product deviating from the instructions given in the SPC, may increase the prevalence of bacteria resistant to ceftiofur.
Povećana primjena, uključujući primjenu proizvoda koja odstupa od uputa iz Sažetka opisa svojstava, može povećati prevalenciju bakterija otpornih na ceftiofur.
Increased uterine bleeding4
pojačano krvarenje iz maternice4
increased warmth in the affected leg
Moždani udar
increased warmth in the affected leg change in colour of the skin on the leg e.g. turning pale, red or blue
povećana toplina zahvaćene noge promjena boje kože na nozi, npr. ako poblijedi, pocrveni ili poplavi
increased warmth in the affected leg;
povećana toplina zahvaćene noge;
increased weight
povećanje tjelesne težine
Increased weight, decreased appetite, increased appetite
povećana tjelesna težina, smanjeni tek, pojačan tek
Increased weight, increased lactate dehydrogenase in the blood, decreased kidney function, increased blood sugar, increased phosphorus in the blood
povećana tjelesna težina, povišena razina laktatdehidrogenaze u krvi, smanjena funkcija bubrega, povišeni šećer u krvi, povišena razina fosfora u krvi
increased weight, nausea, diarrhoea, elevated levels of some liver enzymes
povećana tjelesna težina, mučnina, proljev, povišene razine nekih jetrenih enzima
increased white blood cells
povećan broj bijelih krvnih stanica
increased white blood cells
povećani broj bijelih krvnih stanica
increased yawning
pojačano zijevanje
increased yawning;
pojačano zijevanje
increased)
povišen GGT)
increased, blood LDH
reakcije na mjestu primjene
increased, blood LDH increased, blood TSH increased, lymphopenia,
ALP u serumu, povišen LDH u krvi, povišen TSH u krvi, limfopenija, neutropenija, trombocitopenija
increased.
porasti.
increased/decreased sensitivity to stimuli to senses
povećana/smanjena osjetljivost osjetila na podražaje
increasedd,e (see Special populations)
erektilna disfunkcijae
increased‡
povišena alkalna
Increases above 5 msec were observed in the median/mean QT/QTc intervals in the pooled analysis.
U objedinjenoj su analizi primijećena produljenja medijana/srednje vrijednosti QT/QTc-intervala veća od 5 ms.
increases bone formation in bone tissue culture as well as osteoblast precursor replication and collagen synthesis in bone cell culture. reduces bone resorption by decreasing osteoclast differentiation and resorbing activity.
pospješuje stvaranje kosti u kulturama koštanoga tkiva, kao i umnažanje preteča osteoblasta i sintezu kolagena u kulturi koštanih stanica, smanjuje resorpciju kosti slabeći diferencijacijsku i resorpcijsku sposobnost osteoklasta.
Increases from baseline for lymphocytes, monocytes, eosinophils and basophils ranged from 35% to 140% for individual cell types but mean cell counts remained within normal ranges.
Povećanje broja limfocita, monocita, eozinofila i bazofila kretalo se u rasponu od 35% do 140% za pojedine vrste stanica, ali je srednji broj stanica ostao u normalnim okvirima.
Increases in ALT levels above baseline have been observed in patients treated with Pegasys, including patients with a viral response.
U bolesnika liječenih lijekom Pegasys, uključujući i bolesnike s virološkim odgovorom, zamijećen je rast razina ALT-a iznad početnih vrijednosti.
Increases in blood creatinine levels (a sign of kidney problems, which might lead less frequent urination).
Porast razine kreatinina u krvi (kao znak bubrežnih tegoba, što može rezultirati rjeđim mokrenjem).
Increases in blood glucose levels have been reported with Tasigna therapy (see section 4.4).
Uz liječenje Tasignom zabilježene su povišene razine glukoze u krvi (vidjeti dio 4.4).
Increases in blood levels of liver enzymes.
Porast razine jetrenih enzima u krvi.
Increases in blood urea nitrogen
Porast koncentracije BUN-a
Increases in blood uric acid levels were observed in studies on gouty arthritis patients flaring.
Povećanja razina mokraćne kiseline u krvi uočena su u ispitivanjima na bolesnicima s uričnim artritisom tijekom iznenadnog napada bolesti.
Increases in BMD at the total hip were 0.3, 1.9, and 3.0 for the 3 groups, respectively.
Povećanje BMD u cijeloj bedrenoj kosti bilo je 0,3%, 1,9% odnosno 3,0% u tri grupe istim redoslijedom.
increases in body temperature (fever)
povećanje tjelesne temperature (vrućica)
Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy; however at the 12.5 mg dose contained in Ifirmacombi, minimal or no effects were reported.
Povišenje razine kolesterola i triglicerida bilo je povezano s terapijom tiazidima, međutim, pri dozi od mg koliko sadrži Ifirmacombi, zabilježeni su minimalni učinci ili ih uopće nije bilo.
Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy; however at the 12.5 mg dose contained in the irbesartan and hydrochlorothiazide combination, minimal or no effects were reported.
Povišenje razine kolesterola i triglicerida bilo je povezano s terapijom tiazidima; međutim, pri dozi od 12,5 mg koliko sadrži kombinacija irbesartana i hidroklorotiazida, zabilježeni su minimalni učinci ili ih uopće nije bilo.
Increases in chromosomal aberrations were observed in the peripheral lymphocytes of leukaemic patients, in a renal cell carcinoma patient who received an unstated dose of 6–mercaptopurine and in patients with chronic renal disease treated at doses of 0.4 – 1.0 mg/kg/day.
Povećani broj kromosomskih aberacija zabilježen je u perifernim limfocitima bolesnika s leukemijom, u bolesnika s karcinomom bubrežnih stanica koji je primao nepoznatu dozu 6-merkaptopurina te u bolesnika s kroničnom bolešću bubrega liječenih dozama od 0,4 do 1,0 mg/kg/danu.
increases in creatinine in the blood
povećanu razinu kreatinina u krvi
Increases in levels of uric acid and creatine phosphokinase in the blood
povećanje razine mokraćne kiseline i kreatin fosfokinaze u krvi; pojačan apetit; omaglicu
Increases in lipase activities were transient and were generally not accompanied by signs or symptoms of pancreatitis in subjects with various solid tumours.
Porast aktivnosti lipaze bio je prolazan i uglavnom nije bio popraćen znakovima ili simptomima pankreatitisa u bolesnika s različitim solidnim tumorima.
Increases in liver enzyme activities associated with symptoms of anorexia, apathy or vomiting were uncommon.
Porasti u aktivnostima jetrenih enzima povezani s kliničkim znakovima anoreksije, apatije ili povraćanja bili su manje česti.
Increases in liver enzymes (alanine aminotransferase or aspartate aminotransferase) in laboratory blood tests
Povišeni enzimi jetre (alanin aminotransferaza ili aspartat aminotransferaza) u laboratorijskim pretragama krvi
Increases in liver enzymes (identified in routine liver function testing)
Povišene vrijednosti jetrenih enzima (utvrđene rutinskim testom funkcije jetre)
increases in liver enzymes in the blood (these will show up in blood tests)
povećanje jetrenih enzima u krvi (to će se pojaviti u krvnim testovima)
Increases in liver enzymes were reported in studies with nitrocatechol inhibitors of catechol-O- methyltransferase (COMT).
U ispitivanjima s nitrokatekolskim inhibitorima katekol-O-metiltransferaze (COMT) zabilježen je porast razine jetrenih enzima.
increases in liver enzymes*
povišene vrijednosti jetrenih enzima
Increases in liver enzymes, hyperbilirubinaemia (excess of bile pigment in the blood)
Porast jetrenih enzima, hiperbilirubinemija (višak žučnog pigmenta u krvi)
increases in MCV, decreases in neutrophils
povećanje srednjeg staničnog volumena (MCV), smanjenje broja neutrofila
Increases in mean systolic and diastolic blood pressure, of approximately 3 mmHg and 1 mmHg respectively, above original baseline were observed upon discontinuation of Intuniv.
Nakon prestanka primjene Intuniva bilo je opaženo povećanje srednje vrijednosti sistoličkog krvnog tlaka za približno 3 mmHg i dijastoličkog za približno 1 mmHg u odnosu na originalne početne vrijednosti.
Increases in plasma cinacalcet concentration are similar, regardless of the fat content of the meal.
Povećanje koncentracije sinakalceta u plazmi slično je bez obzira na količinu masti u obroku.
Increases in plasma creatine phosphokinase (CPK; MM isoenzyme) levels associated with muscular pains and/or weakness and cases of myositis, myoglobinaemia and rhabdomyolysis have been reported during therapy with Cubicin (see also sections 4.5, 4.8 and 5.3).
Tijekom terapije Cubicinom zabilježeni su porasti razina kreatin fosfokinaze (CPK; MM izoenzim) u plazmi, povezani s bolovima i/ili slabošću mišića, kao i slučajevi miozitisa, mioglobinemije i rabdomiolize (vidjeti također dijelove 4.5, 4.8 i 5.3).
Increases in plasma exposure to bedaquiline would be expected when it is co-administered with other ritonavir-boosted HIV protease inhibitors.
Povišenje u plazmatskoj izloženosti bedakilinu očekivalo bi se kad se on primjenjuje istovremeno s drugim ritonavir-pojačanim inhibitorima proteaze HIV-a.
Increases in postimplantation loss, reduced foetal body weights and decreased litter sizes together with increases in the number of malformations (gross external, soft tissue) and skeletal alterations (including retarded ossification) were reported in rats receiving doses which produced approximately 2 to 3 fold the clinical exposure (54 mg/m2/day) and in rabbits receiving 12 mg/m2/day clofarabine. (There are no exposure data in rabbits.) The threshold for developmental toxicity was considered to be 6 mg/m2/day in rats and 1.2 mg/m2/day in rabbits.
U štakora koji su primali doze koje su dovele do izloženosti približno 2 do 3 puta veće od one kliničke (54 mg/m2 na dan) te u kunića koji su primali dozu klofarabina od 12 mg/m2 na dan prijavljena je povećana učestalost gubitka ploda nakon implantacije, smanjena tjelesna težina ploda i smanjena veličina legla, uz povećanje broja malformacija (velike vanjske, meko tkivo) i koštanih promjena (uključujući zastoj u osifikaciji). (Nema podataka o izloženosti u kunića.) Smatra se da je prag za razvojnu toksičnost bio 6 mg/m2 na dan u štakora i 1,2 mg/m2 na dan u kunića.
Increases in serum creatinine occurred within the first week of treatment with dolutegravir and remained stable through 96 weeks.
Povećanja koncentracije kreatinina u serumu nastupila su u prvome tjednu liječenja dolutegravirom, nakon čega su vrijednosti bile stabilne do 96. tjedna.
Increases in systemic levels of alpha interferon and other cytokines following topical application of imiquimod were demonstrated in a pharmacokinetic study.
Tijekom farmakokinetičkog ispitivanja dokazano je povećanje razine alfa interferona i drugih citokina u krvi nakon topikalne primjene imikvimoda.
Increases in the amount of glucose excreted in the urine were observed in healthy subjects and in subjects with type 2 diabetes mellitus following the administration of dapagliflozin.
Povećanje količine glukoze izlučene mokraćom primijećeno je nakon primjene dapagliflozina kod zdravih ispitanika i ispitanika sa šećernom bolešću tipa 2.
Increases in the level of sugars in the blood and urine.
povišene razine šećera u krvi i mokraći
Increases in the levels of some liver enzymes
Povišene razine nekih jetrenih enzima
Increases in the levels of some liver enzymes.
Povišene razine nekih jetrenih enzima
Increases in the QTc interval to over 500 msec occurred in 0.5%, and changes from baseline in excess of 60 msec occurred in 1.1% of the 450 solid tumour patients; both of these parameters are recognized as potentially significant changes.
Produljenje QTc-intervala na više od 500 msek pojavilo se u 0,5%, a promjene za više od 60 msek u odnosu na početne vrijednosti u 1,1% od ukupno 450 bolesnika sa solidnim tumorima; oba navedena parametra smatraju se potencijalno značajnim promjenama.
Increases in total serum cholesterol levels have been reported with Tasigna therapy (see section 4.4).
Uz liječenje Tasignom zabilježene su povišene razine ukupnog kolesterola u serumu (vidjeti dio 4.4).
Increases in uric acid level (0.7 mg/dl at 12 weeks and 0.5 mg/dl at 24 weeks) were observed after Ilaris treatment in comparative trials in gouty arthritis.
Povišenja razine mokraćne kiseline (0,7 mg/dl nakon 12 tjedana i 0,5 mg/dl nakon 24 tjedna) bila su uočena nakon liječenja Ilarisom u komparativnim ispitivanjima uričnog artritisa.
Increases in volume, measured radiographically occurred early during filgrastim therapy and tended to plateau.
Prema radiografskim mjerenjima, do povećanja volumena došlo je u ranoj fazi liječenja filgrastimom te je imao tendenciju postizanja platoa.
Increases in volume, measured radiographically, occurred early during filgrastim therapy and tended to plateau.
Povećanje volumena slezene, mjereno radiografski, nastalo bi u početku liječenja filgrastimom i uglavnom dostizalo plato.
Increases in volume, measured radiographically, occurred early during filgrastim therapy and tended to plateau.
Radiografski izmjereno povećanje volumena javljalo se rano pri primjeni filgrastima i pokazivalo tendenciju postizanja platoa.
Increases in your blood sugar level (diabetes)
porast razine šećera u krvi (dijabetes)
Increases in your triglyceride levels (fatty substances in the blood)
Povećanje razine triglicerida (masnoća u krvi)
increases lipogenesis in the liver and adipose tissue and inhibits lipolysis,
povećava lipogenezu u jetri i masnom tkivu te inhibira lipolizu
increases lipogenesis in the liver and adipose tissue and inhibits lipolysis,
povećava lipogenezu u jetri i masnom tkivu te inhibira lipolizu,
increases lipogenesis in the liver and adipose tissue and inhibits lipolysis,
povećava lipogenezu u jetri i masnom tkivu te inhibira lipolizu.
Increases to more than three times the upper limit of normal (ULN) in alanine aminotransferase (ALT) occurred in 1 % of patients receiving Tasmar 100 mg three times daily, and 3 % of patients at 200 mg three times daily.
Povećanja na više od tri puta od gornje granice normale (GGN) u alanin aminotransferazi (ALT) javila su se u 1 % bolesnika koji su primali Tasmar 100 mg tri puta dnevno i 3 % bolesnika koji su primali 200 mg tri puta dnevno.
Increasing age may increase haemorrhagic risk (see section 5.2).
S porastom dobi može biti povećan rizik od krvarenja (vidjeti dio 5.2).
Increasing exposure (AUC) in patients with moderate and severe renal impairment during studies was observed.
Tijekom ispitivanja zapaženo je povećanje izloženosti (AUC, engl. area under the curve) u bolesnika s umjerenim i teškim oštećenjem funkcije bubrega.
Increasing the dose of hydrocortisone at one dose occasion increases the total plasma exposure of cortisol less than proportional, see section 5.2. Once the intercurrent illness episode is over, patients can return to the normal maintenance dose.
Povećanje doze hidrokortizona jednokratnom dozom, poveća ukupnu izloženost kortizola u plazmi manje nego proporcionalno, vidjeti dio 5.2. Kada epizoda istovremene bolesti završi, bolesnik se može vratiti na uobičajenu dozu održavanja.
increasing the dose of other
povećanjem doze drugih
Increasing the dose of ritonavir from that recommended in section 4.2 did not significantly affect darunavir concentrations and is not recommended.
Povišenje doze ritonavira od one preporučene u dijelu 4.2, nije imalo značajan učinak na koncentracije darunavira i ne preporučuje se.
Increasing the dose of Tarceva when co- administered with such agents is not likely to compensate for this loss of exposure.
Povećavanje doze lijeka Tarceva pri istovremenoj primjeni s takvim lijekovima vjerojatno neće nadoknaditi gubitak izloženosti lijeku.
Increasing the infusion time from 5 to 15 minutes caused a 30% decrease in zoledronic acid concentration at the end of the infusion, but had no effect on the area under the plasma concentration versus time curve.
Produljenje trajanja infuzije s 5 na 15 minuta prouzročilo je 30%-tno sniženje koncentracije zoledronatne kiseline na kraju infuzije, ali nije imalo nikakvog učinka na područje ispod krivulje koncentracije u plazmi naspramvremena mjerenja.